Biotech ETF (XBI) ended a diagonal– Looking for purchasing dips
The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that tracks the biotechnology section of the S&P Total Market Index. This ETF permits financiers to acquire direct exposure to big, mid, and small-cap biotech stocks. If you're interested in biotechnology, XBI might be worth checking out even more. Here are a few of its leading holdings and their portion weights: United Therapeutics Corporation (UTHR): 2.92%. Precise Sciences Corporation (EXAS): 2.91%. Gilead Sciences, Inc. (GILD): 2.89%. Sarepta Therapeutics, Inc. (SRPT): 2.87%. Amgen Inc. (AMGN): 2.84%. Alnylam Pharmaceuticals, Inc. (ALNY): 2.65%. Regeneron Pharmaceuticals, Inc. (REGN): 2.64%. Vertex Pharmaceuticals Incorporated (VRTX): 2.60%. AbbVie Inc. (ABBV): 2.60%. BioMarin Pharmaceutical Inc. (BMRN): 2.56%.
In July, we desc...